The list of benefits for Novo Nordisk's semaglutide keeps getting longer. Now, it seems the GLP-1 agonist could help patients with heart failure, adding to earlier studies showing it can treat ...

Heart failure is a complex clinical syndrome affecting around 70 million individuals globally. It has a prevalence of 2% in ...

Novartis’ Entresto is on course to become the first drug to be approved in the US for a form of heart failure that is notoriously hard to treat effectively, despite missing the mark in a phase 3 trial ...

Type 2 Diabetes (T2D) is a major public health challenge, with India ranking second globally in prevalence. [1] The ...